Kiniksa lifts ARCALYST guidance to $1.05bn as Q3 revenue surges 58%
Kiniksa Pharmaceuticals International has raised its full-year revenue guidance for ARCALYST (rilonacept) to between $1.045 billion and $1.050 billion, up from a prior range of $980 million to $995 million, after the recurrent pericarditis therapy generated $286.0 million in net product revenue during the third quarter of 2026. That quarter-on-quarter trajectory represents approximately 58% growth over the $180.9 million recorded in Q3 2025, and the company says the full-year figure will mark ARCALYST's crossing into blockbuster territory.
The London-headquartered, Nasdaq-listed company reported net income of $47.3 million for the quarter, more than doubling the $18.4 million posted in the same period last year, on total revenues that were identical to net product revenue at $286.0 million. As of 30 September 2026, the balance sheet showed $568.8 million in cash, cash equivalents and short-term investments with no debt, giving Kiniksa considerable flexibility to fund its pipeline without near-term recourse to the equity markets.
Commercial momentum in recurrent pericarditis
ARCALYST's growth is underpinned by expanding patient and prescriber uptake within a defined addressable population. Kiniksa estimates approximately 14,000 patients in the US experience annual multiple recurrences; as of the end of Q3, around 23% were actively on ARCALYST treatment, leaving a substantial portion of the market yet to be reached. More than 5,450 prescribers have written ARCALYST prescriptions for the recurrent pericarditis indication since launch, and the average duration of therapy has reached roughly three years, broadly in line with the median duration of the disease itself. That durability metric matters commercially: it suggests patients are remaining on treatment rather than discontinuing, which supports revenue visibility.
ARCALYST is a recombinant dimeric fusion protein that blocks both IL-1α and IL-1β cytokine signalling. It was originally discovered by Regeneron Pharmaceuticals and carries FDA approvals for recurrent pericarditis, cryopyrin-associated periodic syndromes, and deficiency of IL-1 receptor antagonist. The collaboration structure with Regeneron means Kiniksa's income statement includes a significant collaboration expense line, which reached $105.8 million in Q3 2026.
Pipeline: monthly and quarterly dosing candidates advance
Beyond the marketed product, Kiniksa is building a next-generation IL-1 inhibition portfolio targeting the same immunological pathway with improved dosing convenience. KPL-387, an investigational fully human IgG2 monoclonal antibody targeting IL-1 receptor 1, is currently in the PASTORALE Phase 3 pivotal trial in recurrent pericarditis. The randomised withdrawal study is designed around once-monthly subcutaneous dosing. The company expects pivotal data in the second half of 2027, with a commercial launch targeted for 2028 or 2029 if results support regulatory submission.
A supplemental Phase 2 study is also running, evaluating how patients transition from existing standard therapies onto KPL-387 monotherapy, which should generate data relevant to label discussions and prescriber guidance ahead of any potential approval.
Further along in development, KPL-1161 is an Fc-modified IgG2 monoclonal antibody against the same target, designed for quarterly subcutaneous dosing. Kiniksa expects to file for and initiate a Phase 1 first-in-human trial before the end of 2026.
The recurrent pericarditis market is relatively concentrated. ARCALYST was the first and, to date, the dominant approved biologic in the indication in the United States. The shift toward more convenient dosing intervals, from weekly self-injection with ARCALYST to monthly with KPL-387 and potentially quarterly with KPL-1161, reflects a competitive logic familiar from other chronic biologics markets: patient adherence and payer acceptance are sensitive to injection burden. Should KPL-387 data read out positively in 2027, Kiniksa would be positioned to offer a portfolio spanning different dosing profiles within a single mechanism, a defensible franchise model providing the clinical evidence holds.
Kiniksa also guided for 2026 R&D expenses of $160 million to $170 million, and SG&A of $270 million to $280 million, and said its operating plan is expected to remain cash flow positive on an annual basis.